Achieve Life Sciences: Fresh Capital, a New CEO, and a Pivot to US Manufacturing
A Transformational Financing and a New Face
Achieve Life Sciences reported its first quarter 2026 earnings with a clear narrative shift: New CEO Dr. Andrew Goldberg, a $180 million upfront private placement (plus up to $174 million in milestone warrants), and a decisive move to bring manufacturing in-house with U.S.-based Adare Pharma. The market has rewarded the story — the stock surged +128.9% over the last 90 trading days. The private placement not only extends the cash runway but also funds an independent commercial buildout, a departure from earlier partnership discussions.
First, we closed a transformational financing, which positions us for success. This private placement included $180 million in upfront capital, plus up to $174 million from milestone-based warrants...
Goldberg, a dual-boarded physician with 19 board seats, is betting that cytisinicline — a non-nicotine pill for smoking and vaping cessation — finally has the capital and leadership to cross the commercial chasm. The company also added three new board members and two commercial executives from Verona Pharma, including the team behind the Ohtuvayre launch.
Manufacturing and the CRL
The quarter's operational centerpiece is the expected Complete Response Letter (CRL) from the FDA due to a third-party manufacturer's OAI classification. Management quickly pivoted to Adare and now plans to resubmit the NDA in Q4 2026, targeting a commercial launch in H1 2027. The shift to U.S.-based manufacturing also aligns with broader tariff concerns. As Goldberg noted, “we've already moved our manufacturing to the U.S., and we've already produced our first batches this quarter.” — Andrew Goldberg, Chief Executive Officer · 2026-05-12 He later added, “we plan to commercialize independently with our own field force...” — Andrew Goldberg, Chief Executive Officer · 2026-05-12
This is a meaningful evolution from the prior quarter's stance. Just two months ago, the prior CEO said, “the PDUFA date remains the 20th of June of this year.” — Richard A. Stewart, President and Chief Executive Officer · 2026-03-24 Now the company is expecting a CRL, though management insists the observations are not related to cytisinicline. The vaping study (ORCA-V2) is slated to begin this year, funded by the new financing, and the company holds a priority voucher that could accelerate a vaping approval. As the prior CEO described the design, “It's a 2-arm study, placebo for 3 milligram 3 times daily for 12 weeks, roughly 400 patients in each arm.” — Richard A. Stewart, Chief Executive Officer · 2025-11-06
Commercial Strategy at Scale
Goldberg framed nicotine dependence as a disease-awareness play, not a saturation play: “Nicotine dependence is uniquely well suited to a disease awareness and diagnosis approach. Patients already know they have the problem.” — Andrew Goldberg, Chief Executive Officer · 2026-05-12 The commercial team, now built out with Ohtuvayre veterans, will focus on prescriber engagement and removing access friction, using digital and telehealth support. This is bolstered by the field force buildout, a theme that has spiked in the company's keyword trajectory.
Financially, the company remains pre-revenue with deep losses. Net income in the latest quarter was -$10M, though the financing provided substantial capital. The balance sheet now shows $11M in equity, but the liabilities-to-assets ratio sits at 67.7%, reflecting the prior debt burden.
Confluence and Risks
The company is riding a broader wave of interest in US pharma supply chain and tariff mitigation, a theme visible in global keywords. However, the core story is company-unique: a late-stage asset with a resubmission path and a fresh war chest. The stock's recent parabolic move suggests the market already believes in the execution, but the CRL adds a layer of binary risk. The next 12 months will test whether the company can deliver on its NDA timeline and launch effectively.